Pfizer Inc.
30.03USD
-0.3900 (-1.28%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on PFE.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 91.8B | 50.9B | 63.6B | 62.6B | 62.2B | 59.9B |
| Q1 | 25.7B | 18.5B | 14.9B | 13.7B | 14.5B | — |
| Q2 | 27.7B | 13.0B | 13.3B | 14.7B | 15.0B | — |
| Q3 | 22.6B | 13.5B | 17.7B | 16.7B | 15.9B | — |
| Q4 | 15.8B* | 5.9B* | 17.8B* | 17.6B* | 16.9B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 5.47 | .370 | 1.41 | 1.36 | 2.96 | 2.88 |
| Q1 | 1.37 | .970 | .550 | .520 | .470 | — |
| Q2 | 1.73 | .410 | .010 | .510 | -.040 | — |
| Q3 | 1.51 | -.420 | .780 | .620 | .728 | — |
| Q4 | .871* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.590* |
| .072* |
| -.288* |
| .706 |
| — |
Debt level and coverage